Botulinum toxin A injection under electromyographic guidance for treatment of spasmodic dysphonia

Journal of Laryngology and Otology

Volumn 122, Issue 1, 2008, Pages 52-56

  Casserly, P ^a,b   Timon, C ^a  

^a ROYAL VICTORIA EYE AND EAR HOSPITAL   (Ireland)

^b NONE   (Ireland)

Author keywords

Botulinum Toxin Type A; Larynx; Muscles; Spastic Dysphonia; Voice Disorders

Indexed keywords

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPHAGIA; DYSPHONIA; ELECTROMYOGRAM; ELECTROMYOGRAPHY; FEMALE; HUMAN; MALE; OUTCOME ASSESSMENT; PROGNOSIS; SIDE EFFECT; TREATMENT OUTCOME; VOICE CHANGE; DOSE RESPONSE; EVALUATION; INTRAMUSCULAR DRUG ADMINISTRATION; LARYNX DISORDER; METHODOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; AGED; BOTULINUM TOXIN TYPE A; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROMYOGRAPHY; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; TREATMENT OUTCOME; VOICE DISORDERS;

EID: 40349098718     PISSN: 00222151     EISSN: 17485460     Source Type: Journal    
DOI: 10.1017/S0022215107007852     Document Type: Article

References (24)

1. Aronson A. Abductor spastic dysphonia. In: Aronson A, ed. Clinical Voice Disorders, 2nd edn. New York: Thieme Medical Publishing, 1985;187-97
2. Aronson A, Hartman DE. Adductor spastic dysphonia as a sign of essential tremor. J Speech Hear Disord 1981;46:52-8
3. Blitzer A, Brin MF, Fahn S, Lovelace RE. Localised injections of botulinum toxin for the treatment of focal laryngeal dystonia (spastic dysphonia). Laryngoscope 1988;98:193-7
4. Blitzer A, Sulica L. Botulinum toxin; basic science and clinical uses in otolaryngology. Laryngoscope 2001;111:218-26
5. Blitzer A, Brin MF, Stewart CF. Botulinum toxin management of spasmodic dysphonia: a 12-year experience in more than 900 patients. Laryngoscope 1998;98:1435-41
6. Cannito MP, Johnson JP. Spastic dysphonia: a continuum disorder. J Commun Disord 1981;14:215-23
7. Sulica L. Contemporary management of spasmodic dysphonia. Curr Opin Otolaryngol Head Neck Surg 2004;12:543-8
8. Ludlow CL. Treatment of speech and voice disorders with botulinum toxin. JAMA 1990;264:2671-5
9. Dedo HH. Recurrent laryngeal nerve sectioning for spastic dysphonia. Ann Otol Rhinol Laryngol 1979;85:451-9
10. Aronson AE, De Santo LW. Adductor spastic dysphonia: three years after recurrent laryngeal nerve section. Laryngoscope 1983;93:1-8
11. Murry T, Woodson GE. Combined-modality treatment of adductor spasmodic dysphonia with botulinum toxin and voice therapy. J Voice 1995;9:460-5
12. Sheppert AD, Spirou GA, Berrebi J, Garrnet D. Three-dimensional reconstruction of immunolabeled neuromuscular junctions in the human thyroarytenoid muscle. Laryngoscope 2003;113:1973-6
13. Ford CN, Bless DM, Lowery JD. Indirect laryngoscopic approach for injection of botulinum toxin in spasmodic dysphonia. Otol Head Neck Surg 1990;103:752-8
14. Rhew K, Fiedler DA, Ludlow CL. Technique for injection of botulinum toxin through a flexible nasolaryngoscope. Otolaryngol Head Neck Surg 1994;111:787-94
15. Rubin AD, Wodchis WP, Spak C, Kileny PR, Hogikyan ND. Longitudinal effects of Botox injections on Voice-Related Quality of Life (V-RQOL) for patients with adductory spasmodic dysphonia. Arch Otolaryngol Head Neck Surg 2004;130:415-20
16. Zwirner P, Murry T, Swenson M, Woodson G. Effects of botulinum toxin therapy in patients with adductor spasmodic dysphonia: acoustic, aerodynamic, and videoendoscopic findings. Laryngoscope 1992;102:400-6
17. Sapienza CM, Cannito MP, Murry T, Branski R, Woodson G. Acoustic variations in reading produced by speakers with spasmodic dysphonia pre-Botox injection and within early stages of post-Botox injection. J Speech Lang Hear Res 2002;45:830-43
18. Wong DL, Irish JC, Adams SG, Durkin LC, Hunt EJ. Laryngeal image analysis following botulinum toxin injections in spasmodic dysphonia. J Otolaryngol 1995;24:64-8
19. Rodriguez A, Ford C, Bless D, Harmon R. Electromyographic assessment of spasmodic dysphonia patients prior to botulinum toxin injection. Electromyography and Clinical Neurophysiology 1994;34:403-7
20. Benninger MS, Gardiner G, Grywalski C. Outcomes of botulinum toxin treatment for patients with spasmodic dysphonia. Arch Otolaryngol Head Neck Surg 2001;127:1083-5
21. Tisch SH, Brake HM, Law M, Cole IE, Darveniza P. Spasmodic dysphonia: clinical features and effects of botulinum therapy in 169 patients: an Australian experience. J Clin Neurosci 2003;10:434-8
22. Boutsen F, Cannito MP, Taylor M, Bender B. Botox treatment in adductor spasmodic dysphonia: a meta-analysis. J Speech Lang Hear Res 2002;43:469-81
23. Bielamowicz S, Stager SV, Badillo A, Godlewski A. Unilateral versus bilateral injections in patients with adductor spasmodic dysphonia. J Voice 2002;16:117-23
24. Pearson EJ, Sapienza CM. Historical approaches to the treatment of adductor spasmodic dysphonia (ADSD): review and tutorial. Neurorehabiliation 2003;18:325-38